Relationship aggressiveness of prostate cancer with tumor-associated serum markers
Yu.V. Lozovska1, L.A. Naleskina1, T.V. Zadvorniy1, I.M. Andrusishina2, I.V. Zhulkevych3, E.O. Stakhovskiy4, L.M. Kunska1, N.Yu. Lukianova1
- RE. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine,
Kyiv, Ukraine
- SI “Yu.I. Kundiev Institute of Occupational Health”, NAMS of Ukraine, Kyiv, Ukraine
- Ivan Horbachevsky Ternopil National Medical University, Ukraine
- National Cancer Institute, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz65.06.070
Abstract
The content of lactoferrin (LF), C-reactive protein (CRP), albumin, lactate dehydrogenase (LDH), as well
as Ca/Mg and CRP/albumin ratios in sera of patients with prostate cancer were analyzed in relation to the
clinical and pathological features of the disease including the malignancy degree (Gleason score) and the
presence of metastases to regional lymph nodes. In the serum of patients with stage III, LF content was lower
(1.4 times) and CRP/albumin ratio <0.5 than in patients with stage II, while CRP content and Ca/Mg ratio
increased (2.75 and 1.12 times, respectively). In addition, in patients with metastatic lesions of regional
lymph nodes, a decrease in LF content (1.3-fold) and level of albumin (1.16-fold) and a simultaneous increase
in CRP, Ca/Mg (2.84 and 1.1 times, respectively) and CRP/albumin ratios lower (<0.5) were evident. In
serum of patients with tumors of high malignancy degree (8 and 9 points by Gleason score) and prostatespecific
antigen (PSA) level exceeding 4 ng/ml, LF content and CRP/albumin ratio decreased whereas CRP
content and Ca/Mg ratio were increased, LDH activity in serum of these patients also increased significantly.
Therefore, some differences in metabolic pathways in patients with prostate cancer of highly aggressive
course have been elucidated. Comparative study of the content of extratumoral serum PC markers (LF,
PSA, albumin, LDH, Ca/Mg, CRP/albumin), depending on the clinical manifestations of the tumor process
showed that serum LF can be used as an extratumoral marker, which provides new additional information
on the features of the clinical course of the disease.
Keywords:
prostate cancer, tumor-associated biochemical markers, prostate-specific antigen, Gleason score.
References
- Tao ZQ, Shi AM, Wang KX, Zhang WD. Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci. 2015;9(5):805-12.
- Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer. J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.
CrossRef
PubMed
- Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006 May 1;11:1388-413.
CrossRef
PubMed
- Esfahani M, Ataei N, Panjehpour M. Biomarkers for evaluation of prostate cancer prognosis. Asian Pac J Cancer Prev. 2015;16(7):2601-11.
CrossRef
PubMed
- Thorstenson A, Garmo H, Adolfsson J, Bratt O. Cancer specific mortality in men diagnosed with prostate cancer before age 50 years: a nationwide population based study. J Urol. 2017 Jan;197(1):61-6.
CrossRef
PubMed
- Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, Ward EM. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015 Nov 17;314(19):2054-61.
CrossRef
PubMed
- Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69:428-35.
CrossRef
PubMed PubMedCentral
- Hashimoto N. Evaluation of the relationship between C-reactive protein and prostate cancer. Clin Oncol. 2016;1:1005-11.
- Gómez-Gómez E, Carrasco-Valiente J, Campos-Hernández J, et al. Clinical association of metabolic syndrome, Creactive protein and testosterone levels with clinically significant prostate cancer. J Cell Mol Med. 2019 Feb;23(2):934-942.
CrossRef
PubMed PubMedCentral
- Li N, Tian GW, Wang Y, Zhang H, Wang ZH, Li G. Prognostic role of the pretreatment C-reactive protein. albumin ratio in solid cancers: a meta-analysis. Sci Rep. 2017 Jan 27;7:41298.
CrossRef
PubMed PubMedCentral
- Yamashita S, Kohjimoto Y, Iguchi T, et al. A. Prognostic factors and risk stratification in patients with castrationresistant prostate cancer receiving docetaxel-based chemotherapy. BMC Urol. 2016 Mar 22;16:13.
CrossRef
PubMed PubMedCentral
- Wulaningsih W, Holmberg L, Garmo H, et al. Serum lactate dehydrogenase and survival following cancer diagnosis. Br J Cancer. 2015 Nov 3;113(9):1389-96.
CrossRef
PubMed PubMedCentral
- Asare GA, Ngala RA, Afriyie D, et al. Calcium Magnesium imbalance implicatedin benign prostatic hyperplasia and restoration by a phytotherapeutic drug Croton membranaceus Müll. Arg. BMC Complement Altern Med. 2017; Mar 11;17(1):152.
CrossRef
PubMed PubMedCentral
- Fernández-Menéndez S, Fernández-Sánchez ML, González-Iglesias H, et al. Iron bioavailability from supplemented formula milk: effect of lactoferrin addition. Eur J Nutr. 2017;56:2611-20.
CrossRef
PubMed
- Lozovskaya YuV, Lukyanova NYu, Zadvorniy TV, Sobchenko SA, Chekhun VF. Prognostic serum biomarkers of breast cancer: lactoferrin, lactate dehydrogenase and C-reactive protein. Oncol J. 2016;10:33-41. [Belarusian].
- Kizalaite A, Brimiene V, Brimas G, Kiuberis J, Tautkus S, Zarkov A, Kareiva A. Determination of trace elements in adipose tissue of obese people by microwave-assisted digestion and inductively coupled plasma optical emission spectrometry. Biol Trace Elem Res. 2019 May;189(1):10-17.
CrossRef
PubMed
- Kim SW, Lee YJ, Chung LW. A Higher ratio of serum calcium to magnesium is associated with aggressive clinicopathological characteristics in the patients who underwent radical prostatectomy. Korean J Urol Oncol. 2018;16:25-31.
CrossRef
- Sun Y, Selvaraj S, Varma A, et al. Increase in serum Ca2+. Mg2+ ratio promotes proliferation of prostate cancer cells by activating TRPM7 channels. J Biol Chem. 2013 Jan 4;288(1):255-63.
CrossRef
PubMed PubMedCentral
- Baruah SJ, Rajeev TP, Bora SJ. Correlation of serum calcium & magnesium ratio with s. PSA, prostate gland weight & Gleason score in carcinoma prostate a prospective, age matched control study. JASA. 2015;22:6-12.
- Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinsson D, Jungner I, Van Hemelrijck M. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. Int J Cancer. 2018 Jun 1;142(11):2254-62.
CrossRef
PubMed
|